Loading...
XSHE300896
Market cap8.45bUSD
Dec 24, Last price  
204.85CNY
1D
1.44%
1Q
38.52%
IPO
7.76%
Name

Imeik Technology Development Co Ltd

Chart & Performance

D1W1MN
XSHE:300896 chart
P/E
33.17
P/S
21.49
EPS
6.18
Div Yield, %
1.63%
Shrs. gr., 5y
13.39%
Rev. gr., 5y
54.97%
Revenues
2.87b
+47.99%
75,124,088111,817,498140,732,063222,489,964321,011,015557,715,652709,290,1971,447,872,0011,938,838,3632,869,347,231
Net income
1.86b
+47.08%
28,419,40417,652,01053,377,01582,193,507122,854,839305,519,840439,748,783957,979,5851,263,558,4151,858,475,302
CFO
1.98b
+66.00%
27,949,80048,345,80054,997,80084,158,823135,496,573309,715,080425,677,596942,779,5081,193,935,2031,981,901,409
Dividend
Apr 29, 20243.2522 CNY/sh
Earnings
Apr 17, 2025

Profile

Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials. The company offers medical beauty field products, including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. It also offers skin care products, including moisturizing lotions, anti-wrinkle firming kinetic energy liquids, essence creams, hydrating firming masks, chitosan B5 repair sprays, and purifying and brightening kinetic liquids. The company was founded in 2004 and is based in Beijing, China.
URL
https://www.imeik.net/
IPO date
Sep 28, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,869,347
47.99%
1,938,838
33.91%
1,447,872
104.13%
Cost of revenue
531,608
508,096
373,314
Unusual Expense (Income)
NOPBT
2,337,739
1,430,742
1,074,558
NOPBT Margin
81.47%
73.79%
74.22%
Operating Taxes
300,636
220,723
164,504
Tax Rate
12.86%
15.43%
15.31%
NOPAT
2,037,104
1,210,019
910,054
Net income
1,858,475
47.08%
1,263,558
31.90%
957,980
117.85%
Dividends
(1,004,754)
(454,356)
(420,700)
Dividend yield
1.13%
0.37%
0.36%
Proceeds from repurchase of equity
(40,152)
BB yield
0.05%
Debt
Debt current
11,299
7,936
Long-term debt
74,920
96,779
80,371
Deferred revenue
4,148
8,089
Other long-term liabilities
3,372
2
2
Net debt
(5,721,966)
(4,439,691)
(4,388,124)
Cash flow
Cash from operating activities
1,981,901
1,193,935
942,780
CAPEX
(63,681)
Cash from investing activities
(1,265,959)
Cash from financing activities
(1,420,847)
(374,179)
FCF
2,034,746
1,064,777
862,483
Balance
Cash
3,937,226
3,843,273
3,634,051
Long term investments
1,859,660
704,497
842,380
Excess cash
5,653,418
4,450,827
4,404,038
Stockholders' equity
3,474,065
2,535,023
1,618,893
Invested Capital
3,051,807
3,457,065
3,423,775
ROIC
62.59%
35.17%
26.26%
ROCE
35.67%
23.73%
21.27%
EV
Common stock shares outstanding
302,542
216,360
216,360
Price
294.33
-48.03%
566.35
5.64%
536.11
47.32%
Market cap
89,047,333
-27.33%
122,535,486
5.64%
115,992,760
47.32%
EV
83,462,463
118,195,449
111,604,813
EBITDA
2,382,228
1,457,170
1,093,227
EV/EBITDA
35.04
81.11
102.09
Interest
2,384
3,148
2,135
Interest/NOPBT
0.10%
0.22%
0.20%